Phase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients
Overview
Authors
Affiliations
Unlabelled: The aim of this microdosing phase 0 clinical study was to obtain initial information about pharmacokinetics, biodistribution, and specific tumor targeting of the antitenascin-C mini antibody F16SIP.
Methods: Two milligrams of F16SIP, labeled with 74 MBq of (124)I, were intravenously administered to patients with head and neck cancer (n = 4) scheduled for surgery 5-7 d later. Immuno-PET scans were acquired at 30 min and 24 h after injection. For pharmacokinetic analysis, blood samples were taken at different time points after infusion. Tissue uptake was extracted from whole-body PET scans. In addition, ex vivo radioactivity measurements of blood and of biopsies from the surgical specimens were performed.
Results: (124)I-F16SIP was well tolerated. Uptake was visible mainly in the liver, spleen, kidneys, and bone marrow and diminished over time. Tumor uptake increased over time, with all 4 tumors visible on 24-h PET images. The tumor-to-blood ratio was 7.7 ± 1.7 at the time of surgery. Pharmacokinetic analysis revealed good bioavailability of (124)I-F16SIP.
Conclusion: Performing a microdosing immuno-PET study appeared feasible and demonstrated adequate bioavailability and selective tumor targeting of (124)I-F16SIP.The results of this study justify further clinical exploration of (124)I-F16SIP-based therapies.
Advances and challenges in immunoPET methodology.
Mohr P, van Sluis J, Lub-de Hooge M, Lammertsma A, Brouwers A, Tsoumpas C Front Nucl Med. 2024; 4:1360710.
PMID: 39355220 PMC: 11440922. DOI: 10.3389/fnume.2024.1360710.
Wilbs J, Raave R, Boswinkel M, Glendorf T, Rodriguez D, Fernandes E J Med Chem. 2023; 66(12):7772-7784.
PMID: 36995126 PMC: 10292199. DOI: 10.1021/acs.jmedchem.2c02073.
van der Heijden L, van Nuland M, Beijnen J, Huitema A, Dorlo T Clin Transl Sci. 2022; 16(2):258-268.
PMID: 36419385 PMC: 9926085. DOI: 10.1111/cts.13446.
Revisiting the Tenascins: Exploitable as Cancer Targets?.
Tucker R, Degen M Front Oncol. 2022; 12:908247.
PMID: 35785162 PMC: 9248440. DOI: 10.3389/fonc.2022.908247.
Advances in aptamer-based nuclear imaging.
Song W, Song Y, Li Q, Fan C, Lan X, Jiang D Eur J Nucl Med Mol Imaging. 2022; 49(8):2544-2559.
PMID: 35394153 DOI: 10.1007/s00259-022-05782-0.